Roche Concludes the License Agreement with Chugai for AT-527 to Treat COVID-19 in Japan

Shots:

  • Chugai gets exclusive development and commercializing rights for AT-527 in Japan
  • Earlier, Roche and Atea collaborated to jointly develop AT-527. If approved, Atea to distribute AT-527 in the US and Roche will be responsible for global manufacturing and distribution outside the US
  • AT-527 is an investigational, oral, purine nucleotide prodrug, currently being evaluated in a P-II study in patients with moderate COVID-19 requiring hospitalization and patients with mild to mod. COVID-19 who are not hospitalized. A P-III study is expected to start in the H1’21

Click here ­to­ read full press release/ article | Ref: Chugai | Image: Wikipedia

The post Roche Concludes the License Agreement with Chugai for AT-527 to Treat COVID-19 in Japan first appeared on PharmaShots.

Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19

Shots:

  • The companies will collaborate to develop, manufacture, and distribute AT-527 to combat COVID-19. If approved, Atea will be responsible for distributing the treatment option in the US, with the option to request Genentech’s support, and Roche will be responsible for distribution outside the US
  • The therapy is currently being evaluated in P-II study for hospitalized patients with moderate COVID-19 with anticipated P-III initiation in Q1’21, that explores the potential use in patients outside of the hospital setting. Additionally, AT-527 may be developed for post-exposure prophylactic settings
  • AT-527 is an investigational, oral, purine nucleotide prodrug that has demonstrated in antiviral activity against several enveloped single-stranded RNA virus, including human flavivirus and coronavirus

Click here ­to­ read full press release/ article | Ref: Roche | Image: The Times of Israel

The post Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19 first appeared on PharmaShots.